Inclusion Criteria:

-Patients must meet all of the following inclusion criteria:

- Pathologic confirmation of stage III or IV NSCLC.

- Docetaxel therapy for cancer is clinically indicated.

- KPS>=60% *ANC<1,000/mcl and Platelets<100/mcl

Exclusion Criteria:

-Patients must meet none of the following exclusion criteria:

- WBC< 4,000/µl, hemoglobin < 10 g/dl, platelet count < 100,000/µl, total bilirubin >
ULN, AST >1.5 x ULN, alkaline phosphatase > 2.5 x ULN, creatinine > 1.5 mg/dl or
creatinine clearance < 50 ml/min/1.7 m2), (ANC > 10,000/µl)

- Prior docetaxel

- Patient must have recovered from all previous treatment-related toxicity

- Concurrent use of any botanicals for anticancer intent

- Use of Jin Fu Kang or any of its constituent botanicals in the previous three weeks.

- History of allergy to any of the constituent botanicals in Jin Fu Kang.

- Pregnant or lactating women or women of childbearing potential not using effective
contraception. A negative pregnancy test must be documented during the screening
period for women of childbearing potential.

- Concurrent active cancer.

- Concurrent use of immunosuppressives: as an immunostimulant, astragalus-containing
products are contraindicated for patients on immunosuppressive therapy.